Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment

Average (ratings)
No ratings
Your rating


Despite advances in reperfusion with primary stenting, progress in STEMI outcomes has stalled over the past 20 years.  With 90% of coronary blood flow in the capillaries, the answer might be in the microvasculature.(1)  TherOx SSO2 Therapy is the first FDA approved therapy shown to significantly reduce infarct size in STEMI patients.(2)  Pre-clinical studies showed that SSO2 improves microvascular flow, which is strongly associated with mortality and hospitalization for HF within 1 year.(3),(4)   

Learn about the mechanism and data around SSO2 Therapy for STEMI patients.

(1) Kaul S, et al. Circulation. 2004;109:146–149.
(2)  SSO2 Therapy is indicated for use in anterior STEMI patients immediately following primary PCI completed within 6 hours of symptoms onset. 
(3) Spears, et al. J Invas Cardiol 2002;14:160-6.
(4) DeWaha, et al. European Heart Journal (2017) 38, 3502–3510.


To find out more about SSO2 Therapy, visit: https://info.zoll.com/contact-a-product-expert-for-therox-sso2-therapy-zoll


Gregg Stone

Gregg Stone

Robert Kloner

Robert Kloner

This webinar is supported by


Supersaturated Oxygen Therapy (SSO2): The Next Frontier in STEMI Treatment

17:00: Welcome and Introduction

17:03: Stagnant STEMI outcomes

17:08: Why haven't outcomes changed?

17:10: Go beyond PCI to treat the microvasculature

17:22: Supporting clinical data for SSO2 Therapy

17:33: Live Q&A

Learning Objectives

  • To develop an understanding of trends in STEMI treatment
  • To understand the role of microvascular obstruction in outcomes
  • To develop an understanding of SSO2 therapy impact
  • To better understand SSO2 therapy data

Target Audience

  • Interventional Cardiologists
  • Heart Failure Specialists

Faculty Biographies

Gregg Stone

Gregg Stone

Dr Stone is a leading expert in interventional cardiology and is one of the most widely cited researchers in science. He has served as the principal investigator for approximately 130 national and international multicentre randomised trials, has delivered thousands of lectures internationally, and has authored more than 2,500 book chapters, manuscripts and abstracts published in peer-reviewed literature.

Dr Stone is the Director of Academic Affairs for Mount Sinai Heart Health System, and Professor of Medicine and Professor of Population Health Sciences and Policy at The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine, at Mount Sinai, New York.

Dr Gregg Stone is an editorial board member of Interventional Cardiology: Reviews, Research, Resources (ICR3).

View full profile

Robert Kloner

Robert Kloner

Robert Kloner is Chief Science Officer and Scientific Director of Cardiovascular Research at Huntington Medical Research Institutes (HMRI). He serves as Professor of Medicine (Clinical Scholar) at Keck School of Medicine at the University of Southern California. He has run nationally and internationally known cardiovascular research programs for over 40 years, training dozens of medical scientists and collaborating with scores of physician-scientists, numerous research institutions, and medical industries worldwide. During his administrative tenure at both Wayne State University and The Heart Institute of Good Samaritan Hospital, he built successful research facilities from the ground-up, creating centers recognized for scientific excellence and innovation.
Dr Kloner has made major contributions to the understanding and treatment of heart disease, published extensively in medical literature, receiving funding from the National Institutes of Health (NIH), American Heart Association (AHA), Environmental Protection Agency (EPA), Department of Defense (DOD) and numerous corporations and private foundations. 



View full profile